A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of PF-04950615 (RN316) In Healthy Adult Subjects With Hypercholesterolemia.

Trial Profile

A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of PF-04950615 (RN316) In Healthy Adult Subjects With Hypercholesterolemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Oct 2017 Results (n=189) assessing the effect of bococizumab on LDL, VLDL, and HDL particle concentration and size in hypercholesterolemic subjects using patient data pooled from NCT01243151, NCT01342211, and NCT01350141 trials published in the Clinical Therapeutics
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 09 Jul 2012 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top